3rd Nasal Formulation and Delivery Summit

With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However, challenges in biologics formulation, along with renewed interest from major pharmaceutical companies and investors, raise questions about how other companies are addressing development obstacles and the most effective strategies to secure funding.

Dedicated to navigating investment pathways for nasal companies, boosting drug bioavailability in target regions, optimizing translational modelling, and determining the efficacy of delivery devices, the 3rd Nasal Formulation and Delivery Summit will unite biotechs and innovative start-ups to share case studies and best practices in optimizing nasal drug delivery across different therapeutic areas. We will be shining the spotlight on:
- Corporate development strategies around different routes to secure money for start-ups
- Discussing innovative formulation approaches designed to optimize the intranasal delivery route
- Consolidating nasal drug delivery in humans through translational evidence from pre-clinical to clinical settings
- Improving the efficacy of delivery devices to improve target region delivery

Prices:
Drug Developer Pricing - Conference Only: USD 2999.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,
Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,
Academic Pricing - Conference Only: USD 2599.00,
Academic Pricing - Conference + 1 Workshop: USD 3148.00,
Academic Pricing - Conference + 2 Workshops: USD 3697.00,
Solution Provider Pricing - Conference Only: USD 3699.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4448.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5197.00

Speakers: Brian Finrow, Founder and Chief Executive Officer, Lumen Bioscience, Donald Haut, Chief Business Officer, EG 427, Krishna Subramanian, Vice President, Head of Non-clinical andTranslational Science, Seelos Therapeutics, Larry Brown, Executive Vice President and Chief Scientific Officer, Noveome Biotherapeutics, Laura Andrade, Associate Director - Research, Development and Innovation, Insud Pharma, Marc Dean, Chairman, Otologic Research Institute, Parnian Lak, Founder and Chief Executive Officer, Olfera, Qing Zhang, Partner, LDV Partners, Robert Schultz, Venture Partner, Erez Capital, Ryan Kole, Co-Founder, Beyond Barriers Therapeutics, Stewart Low, Chief Operating Officer, Eradivir, Susan Conroy, CEO, Therakind Ltd, Thomas Bradshaw, Chief Executive Officer, Neuronasal, Thomas Joudinaud, CEO, Ceres Brain Therapeutics, Yosef Krespi, Professor, Hofstra University Medical School, Lenox Hill Hospital, NYC, Zachary Warnken, Director, Pharmaceutical Development, Via Therapeutics

Others Details

URL:
Brochure: https://go.evvnt.com/2769487-3?pid=6581